Acute Renal Failure (ARF) Global Market Report 2025

The acute renal failure (ARF) market size has grown strongly in recent years. It will grow from $6.09 billion in 2024 to $6.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to the rising aging population, increasing incidence of sepsis, advancements in diagnostic capabilities, government healthcare initiatives, and the growing number of nephrotoxic medication-related cases.

The acute renal failure (ARF)market size is expected to see strong growth in the next few years. It will grow to $9.09 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the expansion of home-based dialysis solutions, emerging markets, the development of renal biomarkers, increased R&D for new therapeutic drugs, and rising demand for non-invasive diagnostics. Major trends include innovations in continuous renal replacement therapy (CRRT), advancements in 3D bioprinting of renal tissue, the development of wearable biosensors, next-generation dialysis machines, and nanotechnology-driven drug delivery systems.

The rising prevalence of chronic kidney diseases is expected to drive growth in the acute renal failure (ARF) market. Chronic kidney disease (CKD) is a long-term condition in which the kidneys become damaged and lose their ability to filter blood effectively. The increasing occurrence of CKD is largely attributed to the rising rates of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors worldwide. Acute renal failure, which is characterized by the sudden loss of kidney function, can significantly contribute to or worsen CKD by causing permanent damage to kidney tissues, reducing filtration efficiency, and heightening the risk of progressive kidney dysfunction if not properly managed. For example, in June 2023, Kidney Research UK, a UK-based non-profit organization, reported that approximately 7.2 million people in the UK over 10% of the population are currently living with chronic kidney disease. Among them, 3.25 million are in the advanced stages of the disease, while another 3.9 million are in the early stages. By 2033, the number of individuals affected by CKD is projected to increase to 7.61 million. As a result, the growing prevalence of chronic kidney diseases is fueling the expansion of the acute renal failure (ARF) market.

Leading companies in the acute renal failure (ARF) market are prioritizing regulatory approvals for new drugs to extend their reach and solidify their position in treating severe acute kidney injury (AKI). Regulatory approvals involve formal authorization from governmental or regulatory agencies for the marketing and public use of medical treatments, drugs, or devices. For example, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical company, received FDA approval for an Investigational New Drug (IND) application for a Phase 2 trial of Auxora. This trial aims to assess Auxora’s efficacy in treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition with a high mortality rate. Known as the KOURAGE trial, this randomized, double-blind, placebo-controlled study will enroll approximately 150 patients with Stage 2 and 3 AKI who also have AHRF. The study will evaluate the effectiveness of Auxora over five daily doses by measuring the number of days patients remain alive without the need for ventilators or dialysis up to 30 days post-treatment.

In June 2023, Elicio Therapeutics Inc., a US-based biotechnology company, completed a merger with Angion Biomedica Corp. to strengthen its immunotherapy pipeline. Through this merger, Elicio Therapeutics seeks to expand its portfolio by leveraging Angion Biomedica's expertise and resources, accelerating the development of innovative treatments for various diseases, and advancing novel therapies within the biotechnology sector. Angion Biomedica is a US-based biopharmaceutical company specializing in the development of treatments for acute renal failure (ARF).

Major players in the acute renal failure (arf) market are Pfizer Inc., Novartis AG, LG Chem Ltd., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Baxter International Inc., Astellas Pharma Inc., Syensqo, Dr. Reddy's Laboratories Limited, Zydus Lifesciences Limited, NIKKISO Co., Ltd., Quark Pharmaceuticals Inc., NIPRO Corporation, Alloksys Life Sciences B.V., AM-Pharma B.V., Sentien Biotechnologies, MediBeacon LLC, Angion Biomedica Corp., and Atox Bio Ltd.

North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute renal failure (ARF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute renal failure (ARF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute renal failure (ARF), also referred to as acute kidney injury (AKI), is a sudden and rapid decline in kidney function that occurs over a few hours or days. Treatment for ARF involves various approaches, including medication, fluid management, and dialysis, to aid in restoring kidney function and preventing further complications.

The primary types of acute renal failure (ARF) include prerenal, renal, and postrenal ARF. Prerenal ARF results from conditions that impact blood flow to the kidneys, such as dehydration or heart failure. The treatment options consist of various drug classes, including diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, calcium and vitamin D supplements, antibiotics, and other medications. These drugs are administered through different routes, such as oral and intravenous. Diagnosis methods include computed tomography (CT) scans, kidney biopsies, and ultrasounds. ARF treatment is utilized by various end users, including clinics, hospitals, home healthcare providers, and others.

The acute renal failure (ARF) market research report is one of a series of new reports that provides acute renal failure (ARF) market statistics, including acute renal failure (ARF) industry global market size, regional shares, competitors with acute renal failure (ARF) market share, detailed acute renal failure (ARF) market segments, market trends and opportunities, and any further data you may need to thrive in the acute renal failure (ARF) industry. This acute renal failure (ARF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute renal failure (ARF) market consists of revenues earned by entities by providing services such as dialysis treatment, emergency care, renal replacement therapies, post-acute care for kidney recovery, and hospital-based interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute renal failure (ARF) market also includes sales of dialysis equipment, normal saline, urine test kits, and urinary catheters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.